Showing 4851-4860 of 6038 results for "".
- Five-Year Data for Ilumya Show Long-term Efficacy, Safetyhttps://practicaldermatology.com/news/five-year-data-for-ilumya-show-long-term-efficacy-safety/2460698/Long-term data from Phase 3 extension trials for Sun Pharma’s Ilumya (tildrakizumab) in psoriasis show the treatment provided sustained disease control over five years among subjects who were week 28 tildrakizumab responders and etanercept partial responders/nonresponders.
- Industry Responds to COVID-19: NoSweathttps://practicaldermatology.com/news/industry-responds-to-covid-19-nosweat/2460695/Recognizing that any physical activity coupled with wearing a face shield can produce sweat that can get in the eyes and fog-up shields, NoSweat has created the first disposable performance liners specifically for face shields that absorb sweat while preventing fogging, odors, stains, and even ac
- Dermavant: Promising Interim Analysis from Third Phase 3 Trial for Tapinarof in Psoriasishttps://practicaldermatology.com/news/dermavant-promising-interim-analysis-from-third-phase-3-trial-for-tapinarof-in-psoriasis/2460693/Positive results from a planned interim analysis of PSOARING 3, Dermavant Sciences’ long-term, open-label safety study, show that approximately 40 percent of subjects treated with investigational tapinarof cream, 1% achieved complete disease clearance (PGA score = 0). Treatment was well tol
- Breaking Business News: Evolus' Jeuveau Can Stay on U.S. Market For Nowhttps://practicaldermatology.com/news/breaking-business-news-evolus-jeuveau-can-stay-on-us-market-for-now/2460690/Evolus Inc. can remain for sale in the U.S. temporarily while an appeals court re-considers an import ban won by AbbVie Inc.’s Allergan that was slated to go into effect on Feb. 16, 2021, according to
- Ortho Dermatologics Opens Applications for 2021 Aspire Higher Scholarship Programhttps://practicaldermatology.com/news/ortho-dermatologics-opens-applications-for-2021-aspire-higher-scholarship-program/2460683/Ortho Dermatologics opened the application process for its 2021 Aspire Higher scholarship program. The program, which began in 2013, will award nine students who have been treated for a dermatologic condition with a scholarship of up to $10,000 in support of their academic goals. &ldquo
- New NEA Survey Puts Dollar Amounts on Cost of Living with ADhttps://practicaldermatology.com/news/new-nea-survey-puts-numbers-on-cost-of-living-with-ad/2460679/Fully 42 percent of Americans living with atopic dermatitis (AD) spend $1,000 or more out of pocket (OOP) every year to manage their eczema, accrdong to a new survey from the National Eczema Association (NEA). While the median annual estimated OOP expense is $600 across
- Merz Rolls Out Belotero Balance(+) with Lidocaine in the UShttps://practicaldermatology.com/news/merz-rolls-out-belotero-balance-with-lidocaine-in-the-us/2460675/Merz Aesthetics is launching Belotero Balance(+) with Lidocaine in the US. “Healthcare providers can now rely on the well-known rheological properties and performance of Belotero Balance with the time savings and consistency of a pre-mixed lidocaine formulation,” says Patric
- People with Severe Atopic Dermatitis May Have Increased Risk of Death from Several Causeshttps://practicaldermatology.com/news/people-with-severe-atopic-dermatitis-may-have-increased-risk-of-death-from-several-causes/2460673/Although there is limited evidence for overall increased mortality in patients with atopic eczema, those with severe atopic eczema may have a greater risk of dying from several health issues compared with those without eczema, according to a new study in the Journal of Allergy and Clinical Im
- Allergan Aesthetics Introduces CoolSculpting Elitehttps://practicaldermatology.com/news/allergan-aesthetics-introduces-coolsculpting-elite/2460667/Allergan Aesthetics, an AbbVie company, is launching CoolSculptingElite, its next generation fat reduction system with applicators designed to complement the body's natural curves. The system will launch with a new applicator collection, which includes seven different shapes a
- Pulse Biosciences Scores CE Mark for CellFX Systemhttps://practicaldermatology.com/news/pulse-biosciences-scores-ce-mark-for-cellfx-system/2460666/Pulse Biosciences, Inc. received CE mark for the CellFXSystem. The Company can now proceed with its planned controlled launch of the CellFX System to medical practices within the European Union (EU) for the treatment of general dermatologic conditions, including sebaceous hyperplasia (S